Competition & Peer Data API & CSV Delivery

Strongbridge Biopharma Plc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Strongbridge Biopharma Plc (SBBP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2021
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
29.41 %
Q2 2021
Net Margin
-131.86 %
Q2 2021

Key Findings: Strongbridge Biopharma Plc vs Its Competitors

  • TTM: Trailing 12-month revenue of 35M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+15.7% annualized vs trailing 12 months).
  • Peer revenue share: Strongbridge Biopharma Plc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

SBBP Sales vs. its Competitors, Q2 2021

Strongbridge Biopharma Plc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/SBBP/competitors
https://api.csimarket.com/api/v1/companies/SBBP/relationships
https://api.csimarket.com/api/v1/companies/SBBP/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 29.4% for Strongbridge Biopharma Plc. Strongbridge Biopharma Plc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Strongbridge Biopharma Plc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Strongbridge Biopharma plc No Yes Yes No
Similar Growth & Profitability (8) 0.00 % (0 of 8) 100.00 % (8 of 8) 100.00 % (8 of 8) 25.00 % (2 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2021

100%market share
  • Strongbridge Biopharma Plc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Strongbridge Biopharma Plc and its 0 tracked competitors.

See Strongbridge Biopharma Plc's full market share breakdown »

SBBP Stock Performance relative to its Competitors

SBBP Competitors (weighted) Percent change over the selected range

SBBP Stock Performance relative to Similar Growth & Profitability Competitors

SBBP Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range